Carcinotech is a MedTech Contract Manufacturing organisation with expertise in manufacturing 3D printed mini tumours using patient-derived cancer stem cells, primary cells and established cell lines. Carcinotech’s advanced models provide a platform for rapid, ethical, sustainable, and accurate drug discovery, screening, and pre-clinical testing. Working with global partners, leading pharma companies, surgeons, pathologists, clinicians, and industry-leaders, the goal is to accelerate drug discovery and enable delivery of more effective cancer treatments to market. Access to Carcinotech’s AI-driven automated manufacturing allows for accelerated production, with models offering high-throughput capabilities.